1. 191PD_PR9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio. (23rd October 2018) Authors: Conte, P F; Guarneri, V; Bisagni, G; Piacentini, F; Brandes, A A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Frassoldati, A; Musolino, A; Garrone, O; Taverniti, C; Rimanti, A; Sarti, S; Rubino, D; Bologna, A; Vicini, R; Balduzzi, S; D'Amico, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 88OValidation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial. (13th May 2019) Authors: Dieci, M V; Bisagni, G; Brandes, A A; Frassoldati, A; Donadio, M; Garrone, O; Piacentini, F; Balduzzi, S; Guarneri, V; Conte, P F Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0589 The role of anca specificity in the clinical manifestations at disease onset: comparison between patients with granulomatosis with polyangiitis and microscopic polyangiitis. (15th June 2017) Authors: Monti, S; Felicetti, M; Balduzzi, S; Padoan, R; Berti, A; Paolazzi, G; Brunori, G; Schiavon, F; Caporali, R Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. (17th January 2019) Authors: Dieci, M V; Conte, P; Bisagni, G; Brandes, A A; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S Journal: Annals of oncology Issue: Volume 30:Number 3(2019) Page Start: 418 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. (13th September 2018) Authors: Conte, P; Frassoldati, A; Bisagni, G; Brandes, A A; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, C; Rimanti, A; Cagossi, K; Russo, A Journal: Annals of oncology Issue: Volume 29:Number 12(2018) Page Start: 2328 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗